Belite Bio, Inc Short Interest Down 52.8 percent in January
BLTE Stock | USD 57.20 1.06 1.82% |
About 53% of Belite Bio's investor base is interested to short. The analysis of the overall investor sentiment regarding Belite Bio ADR suggests that many traders are impartial. The current market sentiment, together with Belite Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use Belite Bio ADR stock news signals to limit their universe of possible portfolio assets.
Belite |
Belite Bio, Inc was the target of a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 41,800 shares, a decrease of 52.8 percent from the January 15th total of 88,600 shares. Based on an average trading volume of 12,900 shares, the
Read at thelincolnianonline.com
![]() |
Belite Bio Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Belite Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Belite Bio Fundamental Analysis
We analyze Belite Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Belite Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Belite Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Belite Bio is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Belite Bio ADR Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Belite Bio stock to make a market-neutral strategy. Peer analysis of Belite Bio could also be used in its relative valuation, which is a method of valuing Belite Bio by comparing valuation metrics with similar companies.
Peers
Belite Bio Related Equities
GLTO | Galecto | 4.29 | ||||
LRMR | Larimar Therapeutics | 3.77 | ||||
MOLN | Molecular Partners | 3.71 | ||||
CNTA | Centessa Pharmaceuticals | 3.25 | ||||
ANTX | AN2 Therapeutics | 2.70 | ||||
ANAB | AnaptysBio | 2.56 | ||||
GLUE | Monte Rosa | 0.92 | ||||
ALGS | Aligos Therapeutics | 0.66 | ||||
AVTE | Aerovate Therapeutics | 0.41 | ||||
TRDA | Entrada Therapeutics | 0.33 | ||||
AADI | Aadi Bioscience | 0.39 | ||||
ACRV | Acrivon Therapeutics, | 0.56 | ||||
CELC | Celcuity LLC | 0.74 | ||||
ADAG | Adagene | 0.99 | ||||
IMRX | Immuneering Corp | 1.20 | ||||
VIGL | Vigil Neuroscience | 2.02 | ||||
IKNA | Ikena Oncology | 2.19 | ||||
PMVP | Pmv Pharmaceuticals | 2.84 | ||||
ANEB | Anebulo Pharmaceuticals | 3.33 | ||||
MLYS | Mineralys Therapeutics, | 8.23 |
Complementary Tools for Belite Stock analysis
When running Belite Bio's price analysis, check to measure Belite Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Belite Bio is operating at the current time. Most of Belite Bio's value examination focuses on studying past and present price action to predict the probability of Belite Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Belite Bio's price. Additionally, you may evaluate how the addition of Belite Bio to your portfolios can decrease your overall portfolio volatility.
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data |